Skip to content
TrialMatch
Sign up
Recruiting Phase 2

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

Create a profile to match View the full record on ClinicalTrials.gov

About this study

To explore the efficacy and safety of prolonged low-dose decitabine (10 days of 6mg/m2) plus venetoclax (3 weeks/cycle) regimen in primary diagnosed elderly or frail AML/ high-risk MDS.

Condition
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Tested
Decitabine for Injection, VENCLYXTO
Sponsor
First Affiliated Hospital of Zhejiang University

Who can join

Age
60 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 11

  • Minimum age: 60 years
  • Study condition: Acute Myeloid Leukemia, Myelodysplastic Syndromes
  • Patients must be diagnosed with acute myeloid leukemia (non-acute promyelocytic leukemia)/high-risk myelodysplastic syndrome before admission.
  • Diagnostic criteria refer to 2016 WHO classification.
  • Age 60 or older.
  • The scores of physical fitness in the Eastern Tumor Cooperative group (ECOG) ranged from 0 to 3(see Appendix 1).
  • Creatinine clearance ≥30 mL/min(as assessed by the Cockcrod-Gault formula \[Cockcroft et al 1976\] \[13\] or the estimated glomerular filtration rate \[eGFR\] from the Kidney Drink adjustment formula .
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤3× upper limit of normal range (ULN), total bilirubin ≤2×ULN.
  • Echocardiography (ECHO) showed left ventricular ejection fraction (LVEF)≥50% (AHA 2016).
  • Life expectancy \>8 weeks.
  • Sign the informed consent voluntarily, and understand and comply with the requirements of the study.

Exclusion 5

  • Age \<60 years old.
  • Treated patients who had received various chemotherapy regiments.
  • Present clinically significant active cardiovascular disease, such as uncontrolled arrhythmia, uncontrolled hypertension, congestive heart failure, any grade 3 or 4 heart disease as determined by the New York Heart Association (NYHA) functional scale (see Appendix 2), or history of myocardial infarction in the 6 months prior to screening.
  • Other serious diseases that may limit participation in the trial (e.g. advanced infections, uncontrolled diabetes).
  • Those who cannot understand and follow the research plan or sign the informed consent.

Where

1 site, 1 recruiting

The First Affiliated Hospital, College of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.